Indeed, similar to the known SPOP substrate ERG, the protein abundance of ABL1 increased in DU145 prostate cancer cells upon treatment with either the proteasome inhibitor MG132 or the neddylation inhibitor MLN4924 (Fig. 4d). This evidence concerns the gene ABL1 and prostate cancer.